In the last trading session, 6.76 million Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares changed hands as the company’s beta touched 0.90. With the company’s per share price at $7.58 changed hands at -$0.26 or -3.32% during last session, the market valuation stood at $2.17B. RXRX’s last price was a discount, traded about -107.65% off its 52-week high of $15.74. The share price had its 52-week low at $5.22, which suggests the last value was 31.13% up since then. When we look at Recursion Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 5.86 million shares, with the 3-month average coming to 4.91 million.
Analysts gave the Recursion Pharmaceuticals Inc (RXRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.50. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended RXRX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Recursion Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.44.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX was in red as seen at the end of in last trading. With action 11.14%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -23.12%, with the 5-day performance at 11.14% in the green. However, in the 30-day time frame, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is 12.80% up. Looking at the short shares, we see there were 59.44 million shares sold at short interest cover period of 11.89 days.
The consensus price target for the stock as assigned by Wall Street analysts is 11, meaning bulls need an upside of 31.09% from its current market value. According to analyst projections, RXRX’s forecast low is 6 with 12 as the target high. To hit the forecast high, the stock’s price needs a -58.31% plunge from its current level, while the stock would need to tank 20.84% for it to hit the projected low.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Data shows that the Recursion Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -24.58% over the past 6 months, a 1.27% in annual growth rate that is considerably lower than the industry average of 17.00%. Year-over-year growth is forecast to reach 47.70% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 18.17M. 4 analysts are of the opinion that Recursion Pharmaceuticals Inc’s revenue for the current quarter will be 12.97M. The company’s revenue for the corresponding quarters a year ago was 10.89M and 12.65M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 66.80%. The estimates for the next quarter sales put growth at 2.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -43.41%. The 2024 estimates are for Recursion Pharmaceuticals Inc earnings to increase by 1.97%, but the outlook for the next 5-year period is at 12.00% per year.
RXRX Dividends
Recursion Pharmaceuticals Inc is expected to release its next quarterly earnings report in December.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.51% of Recursion Pharmaceuticals Inc shares while 93.52% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 97.94%. There are 93.52% institutions holding the Recursion Pharmaceuticals Inc stock share, with ARK INVESTMENT MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 11.924% of the shares, roughly 28.14 million RXRX shares worth $211.07 million.
BAILLIE GIFFORD & CO holds the second largest percentage of outstanding shares, with 11.266% or 26.59 million shares worth $199.42 million as of 2024-06-30.
